Orange Book Transparency Act of 2020
Sponsored By: Representative Kelly, Robin L. [D-IL-2]
Unknown
Summary
Orange Book Transparency Act of 2019 This bill modifies requirements for the Food and Drug Administration (FDA) to list and publish drug patent and exclusivity information. Specifically, the FDA must include on its list certain patent information and must specify each drug exclusivity period that has not concluded. The holder of an approved drug application must notify the FDA when a listed patent is invalidated by a court or by the Patent Trial and Appeal Board. The FDA must remove invalidated patents from its list, subject to the 180-day drug exclusivity period.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
No Economic Impacts Identified for this Bill
Sponsors & CoSponsors
Sponsor
Kelly, Robin L. [D-IL-2]
IL • D
Cosponsors
Rep. Ruiz, Raul [D-CA-25]
CA • D
Sponsored 4/2/2019
Rep. Rush, Bobby L. [D-IL-1]
IL • D
Sponsored 4/2/2019
Rep. Pallone, Frank [D-NJ-6]
NJ • D
Sponsored 4/2/2019
Rep. Dingell, Debbie [D-MI-6]
MI • D
Sponsored 4/2/2019
Rep. Eshoo, Anna G. [D-CA-16]
CA • D
Sponsored 4/2/2019
Rep. Kennedy, Joseph P., III [D-MA-4]
MA • D
Sponsored 4/2/2019
Rep. Matsui, Doris O. [D-CA-7]
CA • D
Sponsored 4/2/2019
Rep. Craig, Angie [D-MN-2]
MN • D
Sponsored 4/2/2019
Rep. Clarke, Yvette D. [D-NY-9]
NY • D
Sponsored 4/4/2019
Rep. Van Drew, Jefferson [R-NJ-2]
NJ • R
Sponsored 4/4/2019
GREG WALDEN
OR • R
Sponsored 4/4/2019
Rep. Schakowsky, Janice D. [D-IL-9]
IL • D
Sponsored 4/12/2019
Rep. Mucarsel-Powell, Debbie [D-FL-26]
FL • D
Sponsored 5/1/2019
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov